313
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Effect of intratumoral injection on the biodistribution and therapeutic potential of novel chemophor EL-modified single-walled nanotube loading doxorubicin

, , , &
Pages 1031-1038 | Received 03 Apr 2011, Accepted 26 Oct 2011, Published online: 16 Jul 2012

References

  • Foldvari M, Bagonluri M. (2008). Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine, 4:183–200.
  • Foldvari M, Bagonluri M. (2008). Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomedicine, 4:173–182.
  • Ji SR, Liu C, Zhang B, Yang F, Xu J, Long J et al. (2010). Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta, 1806:29–35.
  • Liu Z, Tabakman S, Welsher K, Dai H. (2009). Carbon Nanotubes in Biology and Medicine: In vitro and in vivo Detection, Imaging and Drug Delivery. Nano Res, 2:85–120.
  • Prakash S, Kulamarva AG. (2007). Recent advances in drug delivery: Potential and limitations of carbon nanotubes. Recent Pat Drug Deliv Formul, 1:214–221.
  • Klingeler R, Hampel S, Büchner B. (2008). Carbon nanotube based biomedical agents for heating, temperature sensoring and drug delivery. Int J Hyperthermia, 24:496–505.
  • Tarakanov AO, Goncharova LB, Tarakanov YA. (2010). Carbon nanotubes towards medicinal biochips. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2:1–10.
  • Bianco A, Hoebeke J, Kostarelos K, Prato M, Partidos CD. (2005). Carbon nanotubes: On the road to deliver. Curr Drug Deliv, 2:253–259.
  • Portney NG, Ozkan M. (2006). Nano-oncology: Drug delivery, imaging, and sensing. Anal Bioanal Chem, 384:620–630.
  • Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ. (2007). Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc, 129:8438–8439.
  • Liu Z, Sun X, Nakayama-Ratchford N, Dai H. (2007). Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano, 1:50–56.
  • Liu Z, Tabakman SM, Chen Z, Dai H. (2009). Preparation of carbon nanotube bioconjugates for biomedical applications. Nat Protoc, 4:1372–1382.
  • Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M et al. (2006). Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci USA, 103:3357–3362.
  • Strickley RG. (2004). Solubilizing excipients in oral and injectable formulations. Pharm Res, 21:201–230.
  • Gelderblom H, Verweij J, Nooter K, Sparreboom A. (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer, 37:1590–1598.
  • Chen H, khemtong C, yang X, chang X, gao J. (2010). Nanonization strategies for poorly water-soluble drugs. Drug Discov Today, 16:354–356.
  • Kang MJ, Jung SY, Song WH, Park JS, Choi SU, Oh KT et al. (2011). Immediate release of ibuprofen from fujicalin(®)-based fast-dissolving self-emulsifying tablets. Drug Dev Ind Pharm, 37:1298–1305.
  • Venkatesh G, Majid MI, Mansor SM, Nair NK, Croft SL, Navaratnam V. (2010). In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone. Drug Dev Ind Pharm, 36:735–745.
  • Zhang X, Meng L, Lu Q, Fei Z, Dyson PJ. (2009). Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials, 30:6041–6047.
  • Urva SR, Shin BS, Yang VC, Balthasar JP. (2009). Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci, 877:837–841.
  • Al-Abd AM, Hong KY, Song SC, Kuh HJ. (2010). Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release, 142:101–107.
  • Ali-Boucetta H, Al-Jamal KT, McCarthy D, Prato M, Bianco A, Kostarelos K. (2008). Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chem Commun (Camb), 28:459–461.
  • Chaudhuri P, Soni S, Sengupta S. (2010). Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma. Nanotechnology, 21:025102.
  • Shen K, Curran S, Xu H, Rogelj S, Jiang Y, Dewald J et al. (2005). Single-walled carbon nanotube purification, pelletization, and surfactant-assisted dispersion: A combined TEM and resonant micro-raman spectroscopy study. J Phys Chem B, 109:4455–4463.
  • Strano MS, Moore VC, Miller MK, Allen MJ, Haroz EH, Kittrell C et al. (2003). The role of surfactant adsorption during ultrasonication in the dispersion of single-walled carbon nanotubes. J Nanosci Nanotechnol, 3:81–86.
  • Richard C, Balavoine F, Schultz P, Ebbesen TW, Mioskowski C. (2003). Supramolecular self-assembly of lipid derivatives on carbon nanotubes. Science, 300:775–778.
  • Rastogi R, Kaushal R, Tripathi SK, Sharma AL, Kaur I, Bharadwaj LM. (2008). Comparative study of carbon nanotube dispersion using surfactants. J Colloid Interface Sci, 328:421–428.
  • Han HD, Song CK, Park YS, Noh KH, Kim JH, Hwang T et al. (2008). A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm, 350:27–34.
  • Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Huber P et al. (2006). Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia, 8:788–795.
  • Devalapally H, Rajan KS, Akkinepally RR, Devarakonda RK. (2008). Safety, pharmacokinetics and biodistribution studies of a β-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev Ind Pharm, 34:789–795.
  • Zhang ZH, Yang XY, Zhang Y, Zeng B, Wang ZJ, Zhu TH, Roden RBS, Chen YS, Yang RC. (2006). Delivery of telomerase reverse transcriptase small interfering rna in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Chin Cancer Res, 12:4933–4939.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.